Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 12:5:285.
doi: 10.3389/fmicb.2014.00285. eCollection 2014.

Universal immunity to influenza must outwit immune evasion

Affiliations
Review

Universal immunity to influenza must outwit immune evasion

Sergio Quiñones-Parra et al. Front Microbiol. .

Abstract

Although an influenza vaccine has been available for 70 years, influenza virus still causes seasonal epidemics and worldwide pandemics. Currently available vaccines elicit strain-specific antibody (Ab) responses to the surface haemagglutinin (HA) and neuraminidase (NA) proteins, but these can be ineffective against serologically-distinct viral variants and novel subtypes. Thus, there is a great need for cross-protective or "universal" influenza vaccines to overcome the necessity for annual immunization against seasonal influenza and to provide immunity to reduce the severity of infection with pandemic or outbreak viruses. It is well established that natural influenza infection can provide cross-reactive immunity that can reduce the impact of infection with distinct influenza type A strains and subtypes, including H1N1, H3N2, H2N2, H5N1, and H7N9. The key to generating universal influenza immunity through vaccination is to target functionally-conserved regions of the virus, which include epitopes on the internal proteins for cross-reactive T cell immunity or on the HA stem for broadly reactive Ab responses. In the wake of the 2009 H1N1 pandemic, broadly neutralizing antibodies (bnAbs) have been characterized and isolated from convalescent and vaccinated individuals, inspiring development of new vaccination techniques to elicit such responses. Induction of influenza-specific T cell responses through vaccination has also been recently examined in clinical trials. Strong evidence is available from human and animal models of influenza to show that established influenza-specific T cell memory can reduce viral shedding and symptom severity. However, the published evidence also shows that CD8(+) T cells can efficiently select immune escape mutants early after influenza virus infection. Here, we discuss universal immunity to influenza viruses mediated by both cross-reactive T cells and Abs, the mechanisms of immune evasion in influenza, and propose how to counteract commonly occurring immune-escape variants.

Keywords: T cells memory; antibodies; influenza viruses; vaccine design; viral escape mechanisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Broadly reactive HA-specific Abs can bind different regions of the HA (A,B), which based on the sequence or structural conservation of the region targeted by Abs can lead to reactivity against otherwise highly divergent influenza viruses (C), such as influenza A group 1 and group 2 and even influenza B viruses. The cartoon depiction of the HA protein (A,B) is not to scale. Group 1 and 2 phylogeny of influenza A HA (C) was adapted from Corti and Lanzavecchia (2013).

References

    1. Akondy R. S., Monson N. D., Miller J. D., Edupuganti S., Teuwen D., Wu H., et al. (2009). The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183, 7919–7930 10.4049/jimmunol.0803903 - DOI - PMC - PubMed
    1. Allan W., Tabi Z., Cleary A., Doherty P. C. (1990). Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J. Immunol. 144, 3980–3986 - PubMed
    1. Antrobus R. D., Lillie P. J., Berthoud T. K., Spencer A. J., McLaren J. E., Ladell K., et al. (2012). A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS ONE 7:e48322 10.1371/journal.pone.0048322 - DOI - PMC - PubMed
    1. Askonas B. A., Taylor P. M., Esquivel F. (1988). Cytotoxic T cells in influenza infection. Ann. N.Y. Acad. Sci. 532, 230–237 10.1111/j.1749-6632.1988.tb36342.x - DOI - PubMed
    1. Assarsson E., Bui H. H., Sidney J., Zhang Q., Glenn J., Oseroff C., et al. (2008). Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J. Virol. 82, 12241–12251 10.1128/JVI.01563-08 - DOI - PMC - PubMed